Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

PURPOSE: Decitabine, a DNA-targeted hypomethylating agent, is approved by the United States Food and Drug Administration for treatment of patients with myelodysplastic syndromes (MDS) on a schedule of 15 mg/m(2) administered via intravenous (IV) infusion every 8 hours for 3 days. This study assessed...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Steensma, David P., Baer, Maria R., Slack, James L., Buckstein, Rena, Godley, Lucy A., Garcia-Manero, Guillermo, Albitar, Maher, Larsen, Julie S., Arora, Sujata, Cullen, Michael T., Kantarjian, Hagop
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2009
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879689/
https://ncbi.nlm.nih.gov/pubmed/19528372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.6550
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg